Overview
Fusiomica is a protein engineering company specializing in the design of de novo mini-protein binders using advanced generative AI algorithms. They produce ultra-stable, high-affinity proteins that can target disease sites inaccessible to traditional antibodies, offering cost-effective imaging probes, biopharmaceuticals, and diagnostic reagents. The company partners with pharmaceutical, biotech, and diagnostic organizations to create bespoke binders and deliver experimentally validated constructs.
Financials
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2025-01-01. Active
31 1090 1665 0000 0001 6067 8992- 67 1090 1665 0000 0001 6211 9570
- 16 1090 1665 0000 0001 6449 0877
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Mar 26, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $20,562$20,562 | Marszałek Województwa Małopolskiego | |
| Feb 16, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $33,741$33,741 | Fundacja Startup Hub Poland | |
| Apr 29, 2025 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $1,331$1,331 | Instytut Podstawowych Problemów Techniki Polskiej Akademii Nauk |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
Each member of the management board is authorized to make declarations on behalf of the company independently.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Michał Biśta (42) | 50 | $675.31 | 49.0196% |
Mark Mcalister | 50 | $675.31 | 49.0196% |
Others | 2 | $27.01 | 1.9608% |
Beneficial owners
| Person | Rights | |
|---|---|---|
Michał Justyn Biśta (42)  | Shareholder of a limited liability company, 2500.0 PLN | |
Mark Samuel Beaton Mcalister (59)  | Shareholder of a limited liability company, 2500.0 PLN |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Zawamedsp. z o.o. | $43,909.06 | zawamed.pl | ||
| CadenasP.S.A. | $31,138.51 | cadenas.tech | ||
| NanovelosS.A. | $24,842.03 | nanovelos.com | ||
| Medaisp. z o.o. | $22,311.83 | medai.pl | ||
| Bio2materialssp. z o.o. | $14,121.59 | bio2materials.com | ||
| InventroS.A. | $12,176.61 | inventro.co | ||
| 4cell TherapiesS.A. | $9,123.06 | 4celltherapies.com | ||
| Microbiota Medsp. z o.o. | $7,423.69 | microbiota-med.com | ||
| Poltisssp. z o.o. | $3,843.72 | poltiss.com | ||
| Passio Human Microbiomesp. z o.o. | $1,856.58 | passiohumanmicrobiome.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-04-16 | Share capital change (5,000.00 PLN → 5,100.00 PLN) | |
| 2024-12-19 | Entered in the register |
FAQ
Last updated: 2026-07-04